Aqst stock forecast following a recent biotech conference

Following a recent biotech conference presentation, AQST stock forecast sentiment has tilted bullish. Management’s guidance on market penetration rates exceeded street expectations. In the previous quarter of 2024-06-30, Aquestive Therapeutics Inc's ( NASDAQ:AQST ) actual revenue was $20.10 million, which beat analysts' revenue expectations of $12.38 million by 62.35%. Aquestive Therapeutics Inc's ( NASDAQ:AQST ) actual earnings were -$0.03 per share, which beat analysts' earnings expectations of -$0.113 per share by 73.45%. After releasing the results, Aquestive Therapeutics Inc ( NASDAQ:AQST ) was up by 0.88% in one day. Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report AQST stock forecast remains favorable as the company advances AQST-109 into Phase 3 trials. Market watchers see catalyst-driven volatility ahead, making it a potential swing trade within the biotech basket.